Linked Life Data

1634924

Source:http://linkedlifedata.com/resource/pubmed/id/1634924

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1992-8-25
pubmed:abstractText
A phase II study that alternates the sequence of chemotherapy (carmustine [BCNU], cisplatin [CDDP], and dacarbazine [DTIC]) and biologic therapy (interleukin-2 [IL-2] and interferon alfa-2 alpha [alpha IFN]) was performed to establish a safe and efficacious way to sequence these forms of treatment for metastatic melanoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1338-43
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:1634924-Adult, pubmed-meshheading:1634924-Aged, pubmed-meshheading:1634924-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:1634924-Carmustine, pubmed-meshheading:1634924-Cisplatin, pubmed-meshheading:1634924-Combined Modality Therapy, pubmed-meshheading:1634924-Dacarbazine, pubmed-meshheading:1634924-Drug Administration Schedule, pubmed-meshheading:1634924-Drug Evaluation, pubmed-meshheading:1634924-Female, pubmed-meshheading:1634924-Humans, pubmed-meshheading:1634924-Immunotherapy, pubmed-meshheading:1634924-Interferon-alpha, pubmed-meshheading:1634924-Interleukin-2, pubmed-meshheading:1634924-Male, pubmed-meshheading:1634924-Melanoma, pubmed-meshheading:1634924-Middle Aged, pubmed-meshheading:1634924-Recombinant Proteins, pubmed-meshheading:1634924-Survival Analysis, pubmed-meshheading:1634924-Treatment Outcome
pubmed:year
1992
pubmed:articleTitle
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
pubmed:affiliation
Department of Medicine, University of Chicago, IL 60637.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't